Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Linagliptin Once Daily vs Twice Daily in Healthy Volunteers
NCT02173652Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2008
- Primary completion
- Apr 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve of the analyte in plasma over the time interval 0 to 24 hours at steady state. Started Mar 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02173652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173652.